Karoline W. Schjetne joined Vaccibody in August 2017 as Vice President Scientific Affair. She holds a PhD from University of Oslo, followed by a postdoctoral scholarship where she also worked as visiting researcher at Harvard Medical School. Karoline has worked in both biotech and big pharma industry within the area of immunotherapy and inflammatory diseases since 2007. Karoline is author of several scientific papers in this field and her professional experience spans from development and launch of medical devices to market authorization and product launch, lastly as part of medical affairs in Janssen Pharmaceuticals.
Gunnstein Norheim joined Vaccibody in April 2020 and holds a Ph.D. and a Master’s Degree (Cand. Pharm.) from the University of Oslo, Norway. He has extensive experience in coordinating vaccine science- and early development programs. Gunnstein work includes research in the Oxford Vaccine Group, vaccine development for meningococcal disease and Ebola with the Norwegian Institute of Public Health. He was a member of the Study Steering Group for the Ebola ring vaccination trial in West Africa, and a part of the international WHO-led core team. During Gunnstein’s time at the Coalition for Epidemic Preparedness Innovations (CEPI), he was instrumental in developing the organization from its beginning in 2016 and to a permanent international organization.
Monika Sekelja joined Vaccibody in May 2017 and holds a Ph.D. in Bioinformatics from University of Oslo, Norway. She has extensive experience in developing products that combine genomics, next generation sequencing, molecular biology, machine learning and bioinformatic algorithms. Monika has co-founded and worked in biotech startups within the field of microbiome where she has been involved in engaging cross-functional teams to drive innovative use of genetic/genomic data and analyses. She is the author of numerous scientific papers and patents in the field of bioinformatics, microbiome, and 3D modelling of the human genome.
Einar Jonsbu joined Vaccibody in August 2020 and holds a Ph.D. in Biotechnology from Technical University of Denmark and Norwegian University of Science and Technology. He has a broad experience in leading process development, international technology transfer and manufacturing of biopharmaceutical and pharmaceutical products. His professional career has been both in biotech and big pharma industry covering product areas such as vaccines against microbial and viral infectious diseases, immune oncology, radiopharmaceutical oncology, antibiotics and cell therapy products. Past employments include Xellia Pharmaceutics, Thermo Fisher, Pharmaq, Targovax and Bayer.
Charlotte Qwist joined Vaccibody in September 2020 as Sr Director Clinical Development & Operations. Charlottes strong professional experience stems from leadership roles in global development and clinical operations as well as clinical program management. She has successfully led organizational transformations, international teams and clinical development processes from early clinical phase to late stage development within various therapeutic areas. Charlotte holds a MSc in Pharmacy from Copenhagen University and her past employments include Novo Nordisk, Nycomed, Takeda and Novartis.